This section contains case studies, industry highlights, minireviews, and other articles for drug discovery professionals. Check out the resources page for posters, educational content, lists of drug approvals, and more.
11. The Genentech VPS34 kinase inhibitor, compound 5, is a selective kinase inhibitor that is unusually polar for a kinase inhibitor…
molecule
2 years ago ●
1 min read
12. The Dompé Farmaceutici TRPM8 blocker, compound 59 is a potent (IC50 = 11 nM) compound for painful ocular conditions, with ocular efficacy…
molecule
2 years ago ●
1 min read
13. The Merck Institute antimalarial compound, M5717, is the first plasmodium eEF2 inhibitor to reach clinical development, and is a good…
molecule
2 years ago ●
1 min read
14. The Novartis RET inhibitor, compound 1, demonstrated robust oral in vivo efficacy in RET-driven tumor xenografts at low doses (10 mpk QD).…
molecule
2 years ago ●
1 min read
This month’s cover molecule, BMS-986278, is an LPA1 antagonist and oral (up to 125 mg BID) Ph. II clinical candidate for idiopathic…
molecule
2 years ago ●
2 mins read
The bifunctional degrader, SJ995973, was nominated by Joachim Rudolph. “Instead of the thalidomide-based cereblon binder present in the established BET degrader tool…
molecule
2 years ago ●
1 min read
Load More
